Incidence and associations of Retinal pigment epithelial (RPE) tear post-loading phase of aflibercept 2mg in Treatment Na&#xef;ve Neovascular Age-Related Macular Degeneration (nAMD): PRECISE study report 10

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular DiseasesRetinal Diseases

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebneter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR, Swiss Retina Research Network

doi: 10.1007/s40123-025-01252-6

Macular Diseases

Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study

Ophthalmol Ther

Volpe G, Bonanata M, Peyla A, Ruscitti L, Eggarter V, Pache M, Paris A, Menghini M, Grimaldi G

doi: 10.1007/s40123-026-01431-z

Macular Diseases

The long-term impact of neovascular age-related macular degeneration undergoing routine treatment in first and second eyes on vision-related quality-of-life: FASBAT Report 3

Acta Ophthalmol

Airody A, Hanson RLW, Bunola-Hadfield I, Sivaprasad S, Morland AB, Chakravarthy U, Gale RP, FASBAT study group

doi: 10.1111/aos.70150

Macular Diseases

Adherence to intravitreal aflibercept in neovascular age-related macular degeneration: 24-month results from the ANDROMEDA study

Ophthalmol Retina

Holz FG, Ziemssen F, Bauer Steinhusen U, Wachtlin J, Schürks M, Lorenz K, Scholz P, Machewitz T, Rech C, Lanzl I, Lommatzsch A, Finger RP, ANDROMEDA Study Group

doi: 10.1016/j.oret.2025.09.004

Macular Diseases

Association of Mesopic and Dark-Adapted Retinal Sensitivity With Type 1 Macular Neovascularization in Age-Related Macular Degeneration

Invest Ophthalmol Vis Sci

Karaca I, Wei Y, Nelson R, Sassen SH, Daynes K, Clark F, Brown T, Messina A, Pfau M, Zhang Y, Schmitz-Valckenberg S, Fleckenstein M

doi: 10.1167/iovs.66.15.45

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Macular Diseases

Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society

Invest Ophthalmol Vis Sci

Akada M, Ideyama M, Kido A, Miyata M, Ueda-Arakawa N, Tamura H, Ooto S, Miyake M, Tsujikawa A, Hata M

doi: 10.1167/iovs.67.4.19

Macular Diseases

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration

Clin Exp Ophthalmol

Romano F, Casaluci M, Valastro A, Airaldi M, Milella P, Pozzo Giuffrida F, Cozzi E, Aretti A, Teo KY, Cheung CMG, Nassisi M, Viola F, Staurenghi G, Invernizzi A

doi: 10.1111/ceo.14608

Ophthalmology

Incidence and associations of Retinal pigment epithelial (RPE) tear post-loading phase of aflibercept 2mg in Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD): PRECISE study report 10

Related content

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study

The long-term impact of neovascular age-related macular degeneration undergoing routine treatment in first and second eyes on vision-related quality-of-life: FASBAT Report 3

Adherence to intravitreal aflibercept in neovascular age-related macular degeneration: 24-month results from the ANDROMEDA study

Association of Mesopic and Dark-Adapted Retinal Sensitivity With Type 1 Macular Neovascularization in Age-Related Macular Degeneration

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration